COMP <GO>
FDMT vs MRK // RETURN ON INVESTED CAPITAL (ROIC)
4D Molecular Therapeutics Inc. (NASDAQ) VS. Merck & Company Inc. (NYSE) • 15-METRIC TALLY: FDMT 1
— MRK 9
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: MRK
LAST: $11.90 (-6.89%) • MKT CAP: $706.0M
roic
-28.30%
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
roic
20.70%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (FDMT VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | FDMT | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 74.80% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | -28.30% | 20.70% | -49.00 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 15.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -15.53% | 3.42% | -18.95 | MRK | /fcf-yield <GO> |
| Operating Margin | -60.00% | 34.30% | -94.30 | MRK | /operating-margins <GO> |
| Net Profit Margin | -60.00% | 28.10% | -88.10 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 180.00% | 1.30% | +178.70 | FDMT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 5.17 | 5.19 | -0.02 | MRK | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 7/9 | -2.00 | MRK | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 50.4 | 51.7 | -1.30 | MRK | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.92 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 18.4x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $706.0M | $361.02B | -$360.32B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | FDMT REV | MRK REV | FDMT GROSS % | MRK GROSS % | FDMT FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $85.2M | $65.01B | — | 74.8% | -$109.6M | $12.36B |
| FY 2024 | $37.0K | $64.17B | — | 76.3% | -$138.4M | $18.10B |
| FY 2023 | $20.7M | $60.12B | — | — | -$75.8M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
FDMT // BETA —
MRK // BETA 0.92